Wells Fargo analyst Derek Archila has maintained their bullish stance on KYMR stock, giving a Buy rating yesterday.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Derek Archila has given his Buy rating due to a combination of factors influencing Kymera Therapeutics. Despite Sanofi’s decision to shift focus from KT-474 to KT-485, Archila views this as a minor setback in terms of timeline rather than a significant risk, as Kymera still benefits economically from the program. The core of his optimistic outlook remains centered on KT-621, which is seen as the primary driver of value for the company’s shares.
Additionally, the collaboration with Gilead on the CDK2 degrader adds further validation to Kymera’s platform, offering potential financial benefits through milestone payments and royalties. While the stock experienced a slight decline following the news, Archila believes the fundamental thesis around KT-621 remains strong, anticipating positive movements in the stock as more data becomes available. The strategic partnerships and the continued commitment from Sanofi reinforce confidence in Kymera’s future prospects.
In another report released yesterday, Jefferies also maintained a Buy rating on the stock with a $64.00 price target.